Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).
暂无分享,去创建一个
G. Stone | D. Cohen | M. Reynolds | C. Simonton | A. Durtschi | Y. Lei | E. Magnuson | A. Amin | K. Vilain | Katherine A. Vilain | D. Cohen | D. Cohen
[1] Gregg W Stone,et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. , 2011, Journal of the American College of Cardiology.
[2] M. Jeong,et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. , 2010, Journal of the American College of Cardiology.
[3] Gregg W Stone,et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.
[4] G. Stone,et al. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions. , 2010, JACC. Cardiovascular interventions.
[5] H. Bøtker,et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial , 2010, The Lancet.
[6] K. Anstrom,et al. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Elu , 2009, JACC. Cardiovascular interventions.
[7] G. Stone,et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. , 2006, Journal of the American College of Cardiology.
[8] G. Stone,et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. , 2006, Journal of the American College of Cardiology.
[9] Ameet Bakhai,et al. Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial , 2004, Circulation.
[10] G. Stone,et al. Cost-Effectiveness of Coronary Stenting in Acute Myocardial Infarction: Results From the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial , 2001, Circulation.
[11] P. Serruys,et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. , 1999, Journal of the American College of Cardiology.
[12] A Briggs,et al. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.
[13] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[14] S. Brener,et al. The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials. , 2011, Atherosclerosis.